Deliver Your News to the World

Elsevier’s Inteleos Poised to Launch Integrating Technology for Drug Tracking and Analysis


Elsevier, a world-leading healthcare and scientific publisher, announced today, that it has renewed its agreement with AdvantTechnologies (aTi) paving the way for the launch of the Inteleos Universal IntegratorTM (UI) a revolutionary tool to integrate information on drug pipeline research from multiple sources.

With the Inteleos UI, pharmaceutical and biotech professionals will be able to compare and contrast information from multiple data sources – both internal and external to their organization – streamlining the data collection, analysis and decision making process. The single, intuitive interface presents information from disparate sources in a comprehensive, integrated format that is quick and easy to use.

The Inteleos UI is the first product to offer the ability to conduct single searches across multiple databases. An expanded ontology of scientific terms gives users the ability to conduct an exhaustive search. Advanced functionality includes the ability to “drill down” to the desired level of detail and automatic alerts when there are changes in the data sources.

“It is our quest to develop products that enhance the workflow of researchers,” explains CEO of Elsevier Health Sciences, Brian Nairn. “The agreement with aTi is testament to our commitment to coupling quality content with technology to enhance the research process for business and market intelligence professionals.”

Updated daily, using only primary sources, Inteleos content is structured for maximum user-friendliness and indexed and searchable to meet today’s scientific challenges, including biologics and comprehensive coverage of FDA regulatory filings. Inteleos is the most intuitive, flexible tool for drug pipeline research, tracking and analysis.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.